BioSpace News Archive

Kriya Therapeutics, Inc. today announced the addition of over $150 million in capital committed as part of its Series C Financing, bringing the total Series C round to over $430 million.

Sensus Healthcare, Inc. announces that management will hold a conference call on Thursday, August 3, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2023.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2023 on August 3, 2023.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter 2023 after the market close on Wednesday, August 9, 2023.

Corcept Therapeutics Incorporated announced it will report second quarter financial results and provide a corporate update on August 2, 2023.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 43rd Annual Growth Conference at the InterContinental Boston Hotel.

ViroCell Biologics, a specialist Contract Development and Manufacturing Organisation in cell and gene therapy clinical trials, announces the appointment of Brian Collins as Chief Financial Officer.

Samsung Biologics, the world’s leading contract development and manufacturing organization, announced financial results for the second quarter of fiscal year 2023.

Opthea Limited announced that the American Medical Association’s United States Adopted Names Council, in consultation with the World Health Organization’s International Nonproprietary Names Expert Committee, has approved and adopted the nonproprietary drug name “sozinibercept” for the Company’s lead biologic drug candidate, OPT-302.

United Therapeutics Corporation, announced that it will report its second quarter 2023 financial results before the market opens on Wednesday, August 2, 2023.